旨在对全身磁共振成像 (WBMRI) 对高危前列腺癌 (HRPCa) 患者进行分期的诊断准确性进行叙述性综述，并将其与已建立的成像方式进行比较。使用 PubMed 使用以下内容进行叙述性综述关键词：“全身”、“磁共振成像”、“MRI”、“前列腺癌”、“风险分层”和“分期”。评估 WBMRI 作为对 HRPCa 患者进行分期的成像方式的文章被纳入，而仅评估生化复发或转移性疾病进展的研究则被排除在外。与计算机断层扫描 (CT) 的传统成像相比，具有特异性。此外，与骨闪烁扫描 (BS) 相比，WBMRI 在检测骨转移方面具有更高的灵敏度和特异性。然而，随着用于正电子发射断层扫描（PET）的前列腺特异性膜抗原（PSMA）放射性配体的出现，WBMRI检测转移性疾病的诊断性能显得较差。WBMRI的诊断能力超过了CT和BS的常规成像检测HRPCa 患者的转移性疾病。然而，WBMRI 的表现不如 PSMA PET/CT。需要进一步研究 WBMRI 和 PSMA PET/CT 之间的成本比较，以及需要对组合 PSMA PET/MRI 进行评估。© 2024 BJU International。

To present a narrative review regarding the diagnostic accuracy of whole-body magnetic resonance imaging (WBMRI) in staging patients with high-risk prostate cancer (HRPCa) and compare it to established imaging modalities.A narrative review was carried out using PubMed using the following keywords: 'whole body', 'magnetic resonance imaging', 'MRI', 'prostate cancer', 'risk stratification', and 'staging'. Articles that evaluated WBMRI as the imaging modality to stage patients with HRPCa were included, while studies that solely assessed for biochemical recurrence or metastatic disease progression were excluded.In the evaluation of lymphatic metastases, WBMRI has demonstrated a comparable, if not improved, sensitivity and specificity compared to conventional imaging of computed tomography (CT). Furthermore, WBMRI demonstrates improved sensitivity and specificity in detecting bone metastases compared to bone scintigraphy (BS). However, with advent of prostate-specific membrane antigen (PSMA) radioligands for positron emission tomography (PET), the diagnostic performance of WBMRI to detect metastatic disease appears inferior.The diagnostic capabilities of WBMRI exceed that of conventional imaging of CT and BS in detecting metastatic disease in patients with HRPCa. However, WBMRI does not perform as well as PSMA PET/CT. Further study on cost comparisons between WBMRI and PSMA PET/CT are needed, as well as evaluations of combined PSMA PET/MRI are needed.© 2024 BJU International.